Haemodynamic effects of acute and chronic administration of low-dose carvedilol, a vasodilating β-blocker, in patients with cirrhosis and portal hypertension

Alimentary Pharmacology and Therapeutics

Volumn 16, Issue 3, 2002, Pages 373-380

  Tripathi, D ^a   Therapondos, G ^a   Lui, H F ^a   Stanley, A J ^a   Hayes, P C ^a  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; VASODILATOR AGENT;

ADRENERGIC RECEPTOR BLOCKING; ADULT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CLINICAL ARTICLE; DRUG POTENCY; DRUG TOLERABILITY; FEMALE; HEART OUTPUT; HEART RATE; HEMODYNAMICS; HUMAN; HYPOTENSION; LIVER CIRRHOSIS; LONG TERM CARE; MALE; MEAN ARTERIAL PRESSURE; PORTAL HYPERTENSION; PRIORITY JOURNAL; VENOUS PRESSURE;

CARBAZOLES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION, PORTAL; KIDNEY FUNCTION TESTS; LIVER; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; MALE; PROPANOLAMINES; REGIONAL BLOOD FLOW; VASODILATOR AGENTS;

EID: 0036185720     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2002.01190.x     Document Type: Article

References (30)

1. The effect of propranolol on portal hypertension in patients with cirrhosis: A hemodynamic study
2. Acute and chronic hemodynamic effects of propranolol in unselected cirrhotic patients
3. Increased portal venous resistance hinders portal pressure reduction during the administration of beta-adrenergic blocking agents in a portal hypertensive model
4. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage
5. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis
6. Propranolol prevents first gastrointestinal bleeding in non-ascitic cirrhotic patients. Final report of a multicenter randomized trial
7. Prophylaxis of first hemorrhage from esophageal varices by sclerotherapy, propranolol or both in cirrhotic patients: A randomized multicenter trial
8. Preventive therapy of first gastrointestinal bleeding in patients with cirrhosis; results of a controlled trial comparing propranolol, endoscopic sclerotherapy and placebo
9. Propranolol in the prevention of variceal haemorrhage in alcoholic cirrhotic patients
10. Propranolol in the prevention of the first hemorrhage from esophagogastric varices: A multicenter, randomized clinical trial
11. Nadolol can prevent the first gastrointestinal bleeding in cirrhotics: A prospective, randomized study
12. Nadolol for prophylaxis of gastrointestinal bleeding in patients with cirrhosis. A randomized trial
13. Propranolol in the prevention of first upper gastrointestinal tract hemorrhage in patients with cirrhosis of the liver and esophageal varices
14. A randomised controlled trial for the prevention of the first upper gastrointestinal bleeding due to portal hypertension in cirrhosis: Sclerotherapy or propranolol versus control groups
15. The treatment of portal hypertension: A meta-analytic review
16. Hemodynamic effects of alpha-adrenergic blockade with prazosin in cirrhotic patients with portal hypertension
17. Continuous prazosin administration in cirrhotic patients: Effects on portal hemodynamics and on liver and renal function
18. Comparison of three adrenoreceptor blocking agents in patients with cirrhosis and portal hypertension
19. Propranolol plus prazosin compared with propranolol plus isosorbide-5-mononitrate in the treatment of portal hypertension
20. Pharmakologie und klinische pharmakologie des neuen vasodila tierenden beta-rezeptoren blockers BM 14190
21. Acute haemodynamic changes after oral carvedilol, a vasodilating beta-blocker, in patients with cirrhosis
22. Acute and chronic haemodynamic and renal effects of carvedilol in patients with cirrhosis
23. Carvedilol. A new nonselective beta-blocker with intrinsic anti-Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis
24. Effects of the alpha-/beta-blocking agent carvedilol on hepatic and systemic hemodynamics in patients with cirrhosis and portal hypertension
25. Carvedilol (Carv) vs Propranolol (Prop) in the long term treatment of portal hypertension
26. Clinical pharmacokinetics and pharmacodynamics of carvedilol
27. The pharmacology of carvedilol
28. Stereoselective disposition of carvedilol in man after intravenous and oral administration of the racemic compound
29. Disposition of carvedilol enantiomers in patients with liver cirrhosis: Evidence for disappearance of stereoselective first-pass extraction
30. Drug therapy: Carvedilol